DFX Intelligence
Data Factory
Reading the graph
Reading the graph
CRD 161150
NEW YORK, NY
Data as of (this record's last observation) from federal regulator filings. Page built and rebuilt at most every 15 minutes.
| Fund | Type | Reported GAV | As of | Owners | First reported | Status | Form D file |
|---|---|---|---|---|---|---|---|
| BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP | Private Equity Fund | $1.8B | Apr 12, 2024 | 163 | Mar 27, 2020 | reported | 021-395258 |
| BIOPHARMA SECURED INVESTMENTS III SARL | Private Equity Fund | $345M | Jun 13, 2017 | 76 | Mar 31, 2014 | dropped | 021-199818 |
| BIOPHARMA SECURED INVESTMENTS II, SARL | Private Equity Fund | $138M | Jun 13, 2017 | 51 | Feb 15, 2012 | dropped | 021-157021 |
| PHARMAKON OPPORTUNITIES LP | Private Equity Fund | $46.5M | Apr 12, 2019 | 12 | Mar 29, 2019 | dropped | n/a |
| BIOPHARMA SECURED DEBT FUND, LP | Private Equity Fund | $29.9M | May 1, 2014 | 58 | Feb 15, 2012 | dropped | 021-132649 |
| BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP | Private Equity Fund | $16.7M | Apr 12, 2019 | 2 | Mar 29, 2018 | dropped | n/a |
| BIOPHARMA SECURED INVESTMENTS III PARTNERS, LP | Private Equity Fund | $11.8M | Apr 12, 2019 | 31 | Mar 29, 2018 | dropped | n/a |
| BIOPHARMA SECURED INVESTMENTS III (CAYMAN) FEEDER LP | Private Equity Fund | $5.4M | Apr 12, 2019 | 14 | Mar 29, 2018 | dropped | n/a |
| BIOPHARMA CREDIT INVESTMENTS IV, SARL | Private Equity Fund | $0 | Apr 12, 2023 | 0 | Mar 29, 2016 | reported | 021-252618 |
| Owner | Title | Ownership code | Control person | Acquired | First seen | Last seen |
|---|---|---|---|---|---|---|
| FRIEDMAN, MARTIN, GERSHON | LIMITED PARTNER | C | yes | 01/2013 | Mar 31, 2014 | Apr 12, 2024 |
| GONZALEZ DE COSIO, PEDRO, NMN | CHIEF EXECUTIVE OFFICER, LIMITED PARTNER | C | yes | 04/2009 | Feb 15, 2012 | Apr 12, 2024 |
| GONZALEZ DE COSIO, PEDRO, NMN | MANAGING MEMBER | D | yes | 04/2009 | Feb 15, 2012 | Apr 12, 2024 |
| KIM, DOUGLAS, YEON | CHIEF COMPLIANCE OFFICER | Na | yes | 09/2022 | Oct 7, 2022 | Apr 12, 2024 |
| LEGORRETA, PABLO, GERARDO | LIMITED PARTNER | C | yes | 04/2009 | Feb 15, 2012 | Apr 12, 2024 |
| LEGORRETA, PABLO, GERARDO | MANAGING MEMBER | D | yes | 04/2009 | Feb 15, 2012 | Apr 12, 2024 |
| PHARMAKON MANAGEMENT I LLC | GENERAL PARTNER | C | yes | 04/2009 | Jul 22, 2016 | Apr 12, 2024 |
| Related person | Type | Class on the graph | Its RAUM | Control | Common control | State |
|---|---|---|---|---|---|---|
| RP MANAGEMENT, LLC | n/a | Asset manager | $2.1B | N | yes | n/a |
| BIOPHARMA CREDIT INVESTMENTS V GP LLC | n/a | n/a | n/a | N | no | n/a |
| PHARMA MANAGEMENT (CAYMAN) LTD. | n/a | n/a | n/a | N | yes | n/a |
| PHARMACEUTICAL INVESTORS, LP | n/a | n/a | n/a | N | yes | n/a |
| RP MANAGEMENT IRELAND LTD. | n/a | n/a | n/a | N | yes | n/a |
| RPI EPA HOLDINGS, LP | n/a | n/a | n/a | N | yes | n/a |
| Fiscal year | Filed | RAUM | Discretionary | Employees | Advisory staff | Offices | Private funds | Fund GAV |
|---|---|---|---|---|---|---|---|---|
| 2025 | Mar 31, 2026 | $3.0B | $3.0B | 15 | 9 | 0 | 1 | n/a |
| 2024 | Apr 11, 2025 | $2.9B | $2.9B | 13 | 8 | 0 | 1 | n/a |
| 2023 | Mar 28, 2024 | $3.1B | $3.1B | 12 | 7 | 0 | 1 | $1.8B |
| 2022 | Mar 31, 2023 | $2.9B | $2.9B | 11 | 6 | 0 | 2 | $1.5B |
| 2021 | Mar 29, 2022 | $2.3B | $2.3B | 10 | 6 | 0 | 2 | $929M |
| 2020 | Mar 30, 2021 | $2.2B | $2.1B | 10 | 6 | 0 | 2 | $755M |
| 2019 | Mar 27, 2020 | $1.8B | $1.7B | 8 | 5 | 0 | 2 | $317M |
| 2018 | Mar 29, 2019 | $1.9B | $1.8B | 7 | 4 | 0 | 5 | $380M |
| 2017 | Mar 29, 2018 | $1.6B | $1.6B | 7 | 7 | 0 | 4 | $865M |
| 2016 | Mar 30, 2017 | $915M | $915M | 5 | 5 | n/a | 3 | $1.0B |
| 2015 | Mar 29, 2016 | $970M | $970M | 5 | 5 | n/a | 3 | $918M |
| 2014 | Mar 31, 2015 | $770M | $770M | 5 | 5 | n/a | 2 | $770M |
| 2013 | Mar 31, 2014 | $813M | $813M | 1 | 1 | n/a | 3 | $813M |
| 2012 | Apr 1, 2013 | $398M | $398M | 2 | 2 | n/a | 2 | $484M |
| Latest fiscal year | RAUM | A year earlier | 1y change | Three years earlier | 3y CAGR | Employees | A year earlier | Offices | A year earlier |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $3.0B | $2.9B | 4.5% | $2.9B | 1.6% | 15 | 13 | 0 | 0 |